Barenboim A, et al. - In treating locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC), the clinical and pathologic effectiveness of neoadjuvant FOLFIRINOX was investigated. Researchers identified patients receiving neoadjuvant FOLFIRINOX for LAPC and BRPC treated between 2014-2017. Referral to surgery was made for post-treatment patients achieving resectability, while chemotherapy was continued in unresectable patients. Neoadjuvant FOLFIRINOX rarely achieved resectability in patients with LAPC (10%), while most patients with BRPC undergo resection (87%). Relative to patients undergoing up-front surgery, those receiving neoadjuvant FOLFIRINOX showed a complete pathological response in 13% of cases, tumor downstaging, and a trend towards improved survival.